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Abstract
 Objective—Little is known about the extent of cortical and subcortical volumetric alterations 
that may occur within the first year of HIV infection (primary HIV infection; PHI).
 Design—We used structural MRI in this prospective cross-sectional neuroimaging study to 
determine the extent of volumetric changes in early HIV infection.
 Methods—CSF, blood, NP testing, and structural T1 magnetic resonance imaging scans were 
acquired from 18 HIV- and 47 PHI age-matched, antiretroviral-naïve male participants. Using 
FreeSurfer 5.1, volumetric measurements were obtained from the caudate, amygdala, corpus 
callosum, ventricles, putamen, thalamus, cortical white matter, and total grey matter. Regional 
volumes were compared groupwise and related to biomarkers in cerebrospinal fluid (CSF) [viral 
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load (VL), neopterin, and neurofilament light-chain (NFL)], blood (VL, CD4+, and CD8+ T cell 
count), and neuropsychometric tests [digit-symbol (DSST), grooved pegboard (GPD), finger-
tapping (FT), and timed gait (TG)].
 Results—A trend-level moderate reduction of putamen volume (p=0.076, adjusted Cohen’s 
d=0.5 after controlling for age) was observed for PHI compared to HIV-uninfected individuals. 
Within the PHI group, putamen volume associated with CD4+ count (p=0.03), CD4+/CD8+ Ratio 
(p=0.045), infection duration (p=0.009), and worsening psychomotor performance on the DSST 
(p=0.028), FT (p=0.039), and TG (p=0.009) tests.
 Conclusions—Our volumetric results suggest that the putamen is preferentially susceptible to 
early HIV-associated processes. Examining the natural course of early HIV infection 
longitudinally will allow for mapping of the trajectory of HIV-associated CNS changes, enabling 
creation of improved interventional strategies to potentially stabilize or reverse these observied 
structural changes.
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 INTRODUCTION
HIV enters the central nervous system (CNS) soon after initial infection in the form of free 
virions or by way of immune cells travelling across the blood–brain barrier (BBB) and 
stimulates immune activation [1]. Markers of systemic and microglial immune activation, 
such as CD8+ T cell count and neopterin, are elevated in cerebrospinal fluid (CSF) during 
untreated primary HIV infection (PHI; defined as <1 year after exposure) and remain 
elevated with chronic HIV infection (CHI) (>1 year) in the absence of combination 
antiretroviral therapy (cART) [2, 3]. Viral and immunopathogenic changes that occur during 
PHI may facilitate the subsequent neurodegeneration and cortical and subcortical volume 
loss reported in CHI [4, 5].
However, the existence and extent of brain tissue volume changes early in the course of HIV 
infection are incompletely characterized. One prior study revealed reduced total cortical 
volume and enlarged third ventricle in PHI, though the study included HIV+ individuals 
receiving cART [6, 7]. Thus, the natural course of untreated HIV-dependent volume changes 
is not established, as early initiation of cART may preclude further neural injury. Early 
regional volume loss may be responsible for downstream cognitive performance deficits 
commonly associated with chronic disease [8]. For example, a reduction in putamen size is 
associated with impaired motor performance in CHI [9]. In this study, we obtained cortical 
and subcortical volumetrics in cART-naïve PHI individuals and investigated relationships 
among regional brain volumes, duration of infection, laboratory measures, and 
neuropsychological performance.
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 MATERIALS AND METHODS
 Participants
This study included PHI (n=47) and HIV-uninfected (n=18) participants that have been 
previously described [2, 10, 11]. cART-naïve PHI individuals were assessed within 1 year of 
acquiring HIV as confirmed by recent negative result on HIV antibody testing or results of a 
less-sensitive EIA test [2]. The date of HIV exposure was estimated as 14 days before onset 
of seroconversion symptoms (n=38/47) or as the date halfway between the last negative and 
first positive HIV test (n=9/47). The institutional review board at the University of California 
San Francisco approved the protocol, and informed consent was obtained from all 
participants.
 Specimen sampling, processing, and laboratory studies
Clinical examination (including medical and neurological) and laboratory studies (CSF and 
blood) were obtained. Detailed laboratory analysis for CD4+, CD8+ T cells, CSF neopterin, 
neurofilament light chain (NFL), CSF/plasma albumin ratio, and blood and CSF HIV RNA 
levels have been previously described [10, 11].
 Neuropsychometric performance evaluation
A brief neuropsychometric performance battery was administered to participants and 
included four assessments: timed gait, grooved pegboard, finger tapping, and digit symbol as 
previously described [10]. To control for social and demographic variability in the groups, z-
scores for neuropsychological testing were calculated based on comparing raw scores to age, 
sex, ethnicity, and level of education matched norms. An NPZ-4 score was calculated by 
averaging the four z-scores from the battery [12].
 Neuroimaging acquisition and analyses
T1-weighted three-dimensional magnetization-prepared rapid acquisition gradient echo 
(MPRAGE, TR/T1/TE=2300/950/3 ms, voxel size=1.0×1.0×1.0mm3, flip angle 7°, 
bandwidth=200 Hz/pixel) scans were acquired using a 4T Siemens/Bruker MedSpec scanner 
(Siemens AG, Erlangen, Germany).
Volumetric segmentation was performed using the Freesurfer 5.1 image analysis suite. 
(Harvard University, Boston, MA) [13]. Regional volumes were normalized to total 
intracranial volume (ICV) using a least squares residual regression model. ICV was similar 
across the two groups (p=0.383). Normalized volumes were calculated for the amygdala, 
caudate, putamen, thalamus, third ventricle, corpus callosum, and total white and gray 
matter, regions previously implicated in HIV infection [4, 7].
 Statistical analysis
Demographic characteristics are summarized using means and standard deviations for the 
continuous variables with approximately normal distributions (age, education, NPZ-4), and 
median and first and third quartiles (Q1, Q3) for skewed continuous variables (CD4+ T cells, 
CD8+ T cells, plasma and CSF neopterin, CSF:plasma albumin ratio, CSF WBC), and 
compared between groups using Student’s t-t and Wilcoxon rank-sum test, respectively. For 
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groupwise regional volume comparisons, one-way analysis of covariance (ANCOVA) was 
used with age as a covariate. Regions that showed adjusted volumetric differences between 
the PHI and HIV- group at the 0.10 level were further studied in the PHI group using two-
tailed partial correlation analyses (partialling out age) to examine the associations of 
regional volumes to measures of HIV infection, neuropsychological performance, or 
duration of infection. Appropriate normality transformations (square root and logarithm) 
were used for the skewed variables. No corrections for multiple comparisons were included 
in analysis because of the exploratory nature of the analysis. All statistical analyses used 
SPSS 22 (IBM Corp., Armonk, NY).
 RESULTS
 Participants
PHI participants were assessed at a median 106 days post estimated infection. Table 1 
compares the demographic and laboratory data between the two groups. The PHI and 
control groups did not differ significantly in gender, age, education, or ethnicity. As 
expected, PHI had lower CD4+ T cell count and higher CD8+ T cell and CSF WBC counts. 
CSF: plasma albumin ratio, a measure of BBB integrity, was similar in the two groups, while 
CSF neopterin, a marker of neuroinflammation, was elevated in the PHI group.
 Putamen volume is reduced in PHI
The relative group-wise comparisons of each of the eight target regions can be seen in 
Figure 1A. Total gray and white matter volumes were similar for the two groups, whereas a 
trend-level moderate reduction of putamen volume (p=0.076, adjusted Cohen’s d=0.5 after 
controlling for age) was seen for PHI compared to HIV-uninfected individuals (Figure 1B). 
Cohen’s d is a measure of effect size and is in units of standard deviation. This finding of 
d=0.5 describes a medium-level effect, that, taken together with the trend-level p-value, 
points to a probable, appreciable reduction in putamen volume. It should be noted that 
although the 3rd ventricle appears to have a larger relative groupwise volume difference, this 
difference is not significant (p=0.36) and potentially reflects the high coefficient of variation 
in this region compared to the putamen (average CV3rdVentricle=28% versus average 
CVPutamen=9%). Because of this marginal evidence of a putamen volume reduction in early 
HIV infection, we next explored associations between volume and laboratory measures.
 Putamen volume correlates with systemic immune health measures
In PHI participants, both CD4+ T cell count and CD4+/CD8+ T cell ratio, measures of HIV-
related immune status, showed significant positive correlations with putamen volume (CD4+ 
T cell: rp=0.323, p=0.030; CD4+/CD8+ Ratio: rp=0.304, p=0.045) (Figure 1Ci). PHI 
putamen volume did not significantly correlate with plasma HIV RNA or other CSF 
measures.
 Putamen volume correlates with neuropsychometric performance
The putamen is a basal ganglia structure and is an important component of motor control 
pathways. Therefore, we anticipated a relationship between PHI putamen volume and 
psychomotor performance. We observed significant correlations between putamen volume 
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and normed z-scores from timed gait (rp=0.398; p=0.009), finger tapping (rp=0.312; 
p=0.039), digit symbol substitution (rp=0.331; p=0.028), and the global NPZ-4 score 
(rp=0.442; p=0.003) (Figure 1Cii). Associations between putamen volume and performance 
from timed gait and NPZ4 were only significant in the PHI cohort.
 Putamen volume decreases with longer duration of infection
Putamen volume had a negative relationship with increasing estimated duration of infection 
(p=0.009) (Figure 1D). Though this study is cross-sectional, this finding may imply a 
continuous relationship between duration of infection and putamenal volume loss even 
during the first year of infection.
 DISCUSSION
In this study, we examined regional volumetric differences between individuals within the 
first year of HIV infection and HIV-uninfected individuals. We observed a reduction in 
putamen volume in PHI that associated with duration of infection, neuropsychometric 
performance, and immune system measures.
The putamen (and the basal ganglia collectively) has been shown to be selectively injured in 
a number of diseases, with volume regional loss reported in Type 1 Diabetes [14], multiple 
sclerosis [15], and Alzheimer’s disease [16]. The mechanistic relationships between these 
conditions and HIV may be potentially related to inflammation or vascular injury, and 
warrant further investigation. Though previous studies have reported basal ganglia volume 
loss in HIV, including in chronically infected participants with cognitive impairment [17], 
the mechanism underlying the selective injury to this area remains unclear. In HIV-
associated dementia, HIV replication preferentially occurs in perivascular macrophages in 
the basal ganglia [18], which in its early stages associates with basal ganglia 
hypermetabolism on brain positron emission tomography [19]. Interestingly, the basal 
ganglia is the earliest region to manifest inflammation in magnetic resonance studies of 
acute HIV infection [20], possibly a result of selective impairment of endothelial tight 
junctions observed in this brain region in HIV [21]. Thus, it is possible that even early 
during infection, due to a locally compromised blood brain barrier in the basal ganglia, the 
putamen is an early target of viral infection and inflammatory injury, leading to early tissue 
compromise and volume loss.
These findings, along with previous reports from the same cohort using multiple modalites 
[2, 10, 11], imply a comprehensive narrative of the mechanisms that underlie observed 
pathophsyiological changes seen with early HIV infection. The elevated CSF:plasma 
albumin ratio observed in a larger sample from this cohort and elevated CSF WBC and 
neopterin reported here implies compromised BBB integrity and CNS immune activation in 
PHI [2]. The observed elevated NFL in some HIV+ individuals in this cohort [10] suggest 
neuronal degradation, however we observed no association between NFL and putamen 
volume (rp=−0.103, p=0.497) or other brain volumes. Previously observed changes in white 
matter integrity seen during the first year of infection [11] and our current report of putamen 
volume changes support the concept that early inflammation and neuronal injury measurably 
impact brain structure. While the putamenal volumetric difference was moderate (p=0.076, 
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d=0.5), its biological meaning may be supported by the correlations we observed with 
markers of systemic immune status and duration of HIV infection, possibly reflecting 
cumulative exposure to immune and viral pathogenesis. Furthermore, the biologic 
significance of putaminal volume changes is supported by the relationships noted between 
psychomotor performance and putamen volume. These suggest that subtle changes in brain 
volume could underlie neuropsychological deficits described during early infection [7]. 
Finally, with increasing duration of infection, both functional and structrual connections 
(e.g. prominent white matter tracts) are affected, possibly leading to the more widespread 
neurocognitive changes seen with CHI [11, 22].
This study has several limitations. Because this cohort was designed specifically to examine 
early HIV-associated changes, the HIV-uninfected group was small compared to the PHI 
group. Additionally no adjustments for multiple comparisons were made, exposing the 
results to potential false positive results. Further confirmation of our findings is needed from 
independent studies. Finally, we did not classify the participants according to HIV-associated 
cognitive disorder (HAND) criteria for this analysis as we included a limited testing battery 
and did not formally assess functional status in this cohort [23].
 CONCLUSION
The results reported here add to the contuinally growing body of evidence describing central 
nervous system changes seen early after HIV infection. Collectively, they suggest that early 
intervention may mitigate brain damage, but additional clinical trials are needed.
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Groupwise regional brain volumetric comparisons. A) Among eight regions included in this 
analysis, the putamen was reduced (p<0.1) in primary HIV infection (PHI) compared to 
HIV- individuals. B) Magnitude of putamen volume reduction in PHI. Red line: median 
volume. Green: outlier (>2.7σ). C) Significant (p<0.05) correlations were observed between 
putamen volume and CD4+ T cell count (i) or neuropsychological measures (ii) in PHI 
individuals. D) A decline in cross-sectional putamen volume was associated with increasing 
duration of infection for PHI participants (p<0.01). All correlation coefficients (rp) are 
determined using partial correlation analysis, adjusted for the effects of age.
Wright et al. Page 9









































Wright et al. Page 10
Table 1






Sex (% male) 18 (100) 47 (100) 1.0
Age (years) 35.2 (9.7) 37.1 (9.3) 0.449
Ethnicity, n (%) 0.843
  Caucasian 12 (67) 34 (72)
  African-American 4 (22) 6 (13)
  Asian 2 (11) 4 (9)
  Other 0 (0) 3 (6)
Education in years (SD) 16.1 (2.7) 15.4 (2.4) 0.330
CD4+ T cell count (IQR) 793 (739, 1003) 539 (387, 723) <0.001
CD8+ T cell count 476 (316, 744) 924 (714, 1195) <0.001
Plasma Neopterin 4.5 (3.3,7.3) 12.6 (9.0,18.0) <0.001
CSF Neopterin 4.5 (4.3,4.6) 8.6 (6.8,15.6) <0.001
Plasma HIV-1 viral load (log10) 4.6 (4.0, 5.1)
CSF HIV-1 viral load (log10) 2.6 (1.7,3.1)
CSF:Plasma albumin ratio 4.5 (3.3,7.3) 4.6 (3.8,6.7) 0.861
CSF WBC 1.0 (1.0,3.0) 6.0 (3.5, 9.5) <0.001
CSF NFL 519 (398, 740)
Duration of Infection (months)
(SD)2 4.0 (2.1)
NPZ-4 −0.38 (0.9) −0.03 (0.72) 0.151
Mean (SD), Median (Q1, Q3), or Number (%) per group are shown
1
Determined using Student’s t-test (age, education, NPZ-4), Wilcoxon rank-sum test (CD4+ T cells, CD8+ T cells, plasma and CSF neopterin, 
CSF/plasma albumin ratio, CSF White Blood Cell count), and Fisher’s exact test (ethnicity).
2
For PHI, duration of infection was calculated from date of estimated HIV transmission in the context of laboratory-confirmed recent infection.
PHI= primary HIV infection; NPZ-4= neuropsychological performance Z score; CSF= cerebrospinal fluid; NFL= neurofilament light chain; SD= 
standard deviation; IQR= interquartile range; WBC=white blood count
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